# A Phase II Study to Evaluate the Efficacy of IdeS to Desensitize Transplant Patients With a Positive Crossmatch Test

> **NCT02790437** · PHASE2 · COMPLETED · sponsor: **Hansa Biopharma AB** · enrollment: 19 (actual)

## Conditions studied

- Kidney Failure, Chronic

## Interventions

- **DRUG:** IdeS
- **PROCEDURE:** Kidney transplantation

## Key facts

- **NCT ID:** NCT02790437
- **Lead sponsor:** Hansa Biopharma AB
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-06
- **Primary completion:** 2017-12-12
- **Final completion:** 2018-07-03
- **Target enrollment:** 19 (ACTUAL)
- **Last updated:** 2021-05-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02790437

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02790437, "A Phase II Study to Evaluate the Efficacy of IdeS to Desensitize Transplant Patients With a Positive Crossmatch Test". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02790437. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*